A combined analysis of two phase IIIb studies of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLCF. de Marinis,H. Tu,K. K. Laktionov,J. Feng,A. Poltoratskiy,J. Zhao,I. Egorova,E-H. Tan,M. Gottfried,V. Lee,D. M. Kowalski,C-T. Yang, B. J. Srinivasa,A. Passaro, L. Clementi,W. Tang, D. C-L. Huang,A. Cseh,C. Zhou,Y-L. WuAnnals of Oncology（2019）引用 0|浏览65暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
